Catalent Pharma Solutions has opened a new European Development and Clinical Services Lab in Swindon, UK, expanding its geographic reach for Analytical Development Services. The new lab is located within Catalent’s Swindon campus, joining the development and commercial supply operations for Catalent’s oral fast dissolve Zydis technology.

The lab systems being implemented are designed to meet regulatory requirements in the EU, U.S. and other major markets. The lab services initially offered include: raw material and finished product release testing, qualified person release, method development and validation, compendial testing, microbiology, and stability testing and storage.

“This is part of Catalent’s continuous investment to strengthen our position as the #1 global partner for drug development and formulation services,” said Scott Houlton, president of Catalent’s Development & Clinical Services business. “Our customers have asked for expanded testing services in Europe, and value the expertise and security that come from working with a company with the depth and breadth of Catalent. This expansion will enable us to better meet customer needs in Europe for analytical testing, including clinical and commercial release testing of their products.”